Clinical Trial Detail

NCT ID NCT02621151
Title Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors New York University School of Medicine
Indications

bladder urothelial carcinoma

Therapies

Pembrolizumab

Gemcitabine

Age Groups: adult

No variant requirements are available.